Oryzon Genomics S.A./€ORY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Oryzon Genomics S.A.
Oryzon Genomics S.A. is a Spanish biotechnology company focused on developing innovative therapies through the discovery and development of epigenetic therapeutics. Founded in 2000 and headquartered in Madrid, Spain, Oryzon's research concentrates on LSD1 inhibitors, primarily for oncology and neurodegenerative diseases. The company's leading compounds include iadademstat for cancer treatment and vafidemstat for neurological conditions. Oryzon's unique position in the epigenetics field is supported by its extensive intellectual property portfolio and strategic partnerships with leading pharmaceutical entities. The company operates within the broader pharmaceutical and biotechnology industry, with a specific focus on drug discovery and development.
- Ticker
- €ORY
- Sector
- Health
- Primary listing
- BME
- Employees
- 46
- Headquarters
- Cornellà de Llobregat, Spain
- Website
- www.oryzon.com
ORY Metrics
BasicAdvanced
€203M
-
-€0.05
-
-
Price and volume
Market cap
€203M
52-week high
€3.47
52-week low
€2.65
Average daily volume
214K
Financial strength
Interest coverage (TTM)
-18,479.22%
Profitability
EBITDA (TTM)
-11.4
Effective tax rate (TTM)
42.85%
Management effectiveness
Valuation
Growth
Earnings per share change (TTM)
28.70%
3-year earnings per share growth (CAGR)
-9.37%
What the Analysts think about ORY
Analyst ratings (Buy, Hold, Sell) for Oryzon Genomics S.A. stock.
Analyst projections of the future price of Oryzon Genomics S.A. stock.
ORY Financial Performance
Revenues and expenses
ORY Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.